帕尼培南/倍他米隆治疗小儿难治性化脓性脑膜炎的疗效与安全性  

Panipenem/Betamipron in the Treatment of Refractory Suppurative Meningitis in Children

作　　者：陈茜茜 Chen Qianqian(Hainan Provincial Maternal and Child Health Hospital,Hainan Haikou 570206,China)

机构地区：[1]海南省妇幼保健院,海南海口570206

出　　处：《儿科药学杂志》2019年第6期16-19,共4页Journal of Pediatric Pharmacy

摘　　要：目的:评价帕尼培南/倍他米隆治疗小儿难治性化脓性脑膜炎的临床疗效及安全性。方法:收集2011年7月至2017年7月我院儿科收治的难治性化脓性脑膜炎患儿63例,分成帕尼培南/倍他米隆组与美罗培南组,观察两组患儿的临床疗效和不良反应。结果:美罗培南组30例,有效率93. 33%,细菌培养阳性率为53. 33%,细菌清除率81. 25%;帕尼培南/倍他米隆组33例,总有效率90. 91%,细菌培养阳性率为57. 58%,细菌清除率84. 21%,两组患儿有效率、细菌培养阳性率、细菌清除率比较差异无统计学意义(P均>0. 05)。治疗后美罗培南组出现口腔白色念珠菌感染4例,帕尼培南/倍他米隆组出现3例,差异无统计学意义(P>0. 05)。所有患儿均未出现明显肝肾功能损伤,无过敏反应。结论:帕尼培南/倍他米隆治疗小儿难治性化脓性脑膜炎安全且疗效确切。Objective:To evaluate the clinical efficacy and safety of panipenem/betamipron in the treatment of refractory suppurative meningitis in children.Methods:A total of 63 children with refractory suppurative meningitis admitted into the pediatrics of our hospital from Jul.2011 to Jul.2017 were extracted to be divided into the panipenem/betamethamide group and the meropenem group,the clinical efficacy and adverse drug reactions of two groups were observed.Results:There were 30 cases in the meropenem group,the effective rate was 93.33%,the positive rate of bacterial culture was 53.33%,and the bacterial clearance rate was 81.25%;the panipenem/betamideron group was 33 cases,the effective rate was 90.91%,the positive rate of bacterial culture was 57.58%,and the bacterial clearance rate was 84.21%,with no statistically significant difference between two groups(P>0.05).After treatment,there were 4 cases of oral Candida albicans infection in the meropenem group and 3 cases in the panipenem/betamipron group,the difference was not statistically significant(P>0.05).No obvious hepatic and renal function injury and no allergic reaction were observed in both groups.Conclusion:Panipenem/betamipron is safe and effective in the treatment of refractory purulent meningitis in children.

关 键 词：难治性化脓性脑膜炎 美罗培南 帕尼培南/倍他米隆 

分 类 号：R725.1[医药卫生—儿科]